Month: June 2017

Blue Horseshoe Stocks: NIHD Review & More

NII Holdings, Inc. NIHD

We initially tagged NIHD in our premarket report from last Thursday, and on that day we would observe a low of .5472 in the stock. It’s been stepping its way up, but this morning in premarket trading things have really kicked into high gear, with NIHD cracking through the dollar barrier.

As of this morning’s premarket high of 1.14, we’ve now witnessed an increase of 108% in NIHD over a span of just three trading sessions. In order for us to remain highly interested in this play, we’ll want to see it maintain support at or above its current 50DMA of .83 on any pullbacks that may occur.

Celsion Corp. CLSN

We called out CLSN in yesterday morning’s premarket report, and saw a modest yet respectable move out of that play as well. From a low of 3.85 the stock ran as high as 4.96, marking an intraday move of 29%

The stock was number four on the NASDAQ’s top gainer list for the day, and while it did end up tapering back to close near its daily lows, this morning it is gapping up again in the premarket. This surge of activity is primarily due to yesterday’s announcement of positive results in its ovarian cancer treatment trials.

We’ll definitely be keeping CLSN on our radars and watching for the continued establishment of higher lows off of our recently observed bottom.

Bitcoin Services, Inc. BTSC

BTSC was a part of the bitcoin watchlist we issued on May 25th in the midst of a bitcoin frenzy where the crypto-currency was soaring to new all-time highs.

The residual effect for plays like BTSC has been impressive, with with stocks PPS making a jump from our observed low of  .0366 up to a new high of .164 yesterday, which represents a 348% rip which occurred over a period of just seven sessions.

Egalet Corp. EGLT

Not only is EGLT coming off of a bottom on the chart, but in the space of the past 36 hours, the company has made two major announcements.

Yesterday, it was made known that EGLT had “received a U.S. patent for its proprietary Guardian™ Technology tablet architecture used to create precise delivery of combination products with immediate-, delayed- and/or extended-release properties.” (>>View PR)

Today, the announcement was that “one of the largest payers in the United States will provide coverage of ARYMO® ER (morphine sulfate) extended-release tablets” (>>View PR)

Extended Watchlist:
KMI, GAHC, EBIO, GALT, IAG, BLDP, SBGL

Blue Horseshoe Stocks: CNXS Recap & More

Connexus Corp. CNXS

After initially tagging CNXS on Thursday May 25th amid a major spike of bitcoin hysteria, we witnessed a low of .0007 in the stock, and in the six sessions that have followed it has been building up quite a head of steam.

From that initial observed low, CNXS has gone on to hit a high of .003. which represents a very nice move of 329% while volume over this recent period has been heightened considerably.

We’ve been noticing a few other newsletters finally catching on, but to our knowledge we were the first to the party on CNXS. We’ll continue to monitor its progress moving forward, and will remain interested provided it holds support at or above a previous area of resistance at .0018 on any pullbacks.

FitBit, Inc. FIT – Options Idea

After sitting on the sidelines for many months on FIT, and watching the stock get crushed, we’ve seen it beginning to come up off of its recently established 52-week lows and are beginning to see it as a potential value play.

If our inkling is correct, a play of FIT stock itself would likely work out rather well over the longer term, but as our readers are aware, we like to try to score big with options plays when an opportunity presents itself.

In this case, we’d like to signal a range of extended-term contracts with an August expiration, namely, the FIT 08/18 $5-7 Calls. This will give us plenty of time for FIT to restablish itself and hopefully mount the recovery that appears possible given the current look of the chart.


Celsion Corp. CLSN

Speaking of bottom plays, we’re noticing that CLSN has recently registered a new annual low on Wednesday, and has been attempting to gain some traction and come up off of that bottom.

With the stock very close to extreme oversold territory, we’ll want to place it on watch as a possible rebound play.

Extended Watchlist:
DVAX, HMNY, PERI, RFP, EXTR, FOR

Blue Horseshoe Stocks: Options, Bottom-Plays & More

Dollar General Corp. DG – Recap

After a beat on sales and profits for the quarter and a chart primed for a bullish move, we highlighted the DG Weekly $75-78 Calls and we’re happy to report that each and every one of the contracts contained within that range recorded huge intraday moves for us.

Regardless which set of the seven was chosen, multi-bag gains were there for the taking:

$75 Calls – Range: .92-3.10 – Max Gain: 237%
$75.50 Calls – Range: .64-.2.22 – Max Gain: 247%
$76 Calls – Range: .40-2.05 – Max Gain: 412%
$76.50 Calls – Range: .24-1.20 – Max Gain: 400%
$77 Calls – Range: .12-1.21 – Max Gain: 908%
$77.50 Calls – Range: .06-.80 – Max Gain: 1233%
$78 Calls – Range: .05-.45 – Max Gain: 800%

_______

Lululemon Athletica LULU – Fresh Ideas

Lululemon had an earnings beat of its own yesterday post-market, so we want to formulate some ideas for the LULU chain as well.

Not only is the stock gapping up on earnings, but like DG yesterday, the LULU chart was already looking like a bottom-play with premium potential. That’s why we want to formulate both a short and long term set of ideas for LULU options. The LULU Weekly $55-57.50 Calls*, to coincide with the immediate boost in activity off of these earnings, and the LULU 06/30 58.50-60.50 Calls in the event of a protracted recovery.

*We never highlight options with a weekly expiration on a Friday without an explicit warning. That should tell you how risky it can be. So if you’re not an expert trader, don’t even think about it!

Synergy Pharmaceuticals, Inc. SGYP

We also want to put SGYP on watch today after noticing that the stock is coming off of its 52-week lows. That’s always a chart setup that we’re going to look at, but in this case the lows followed shartly after the company producing positive Phase III data on its TRULANCE™ drug, which is already approved by the FDA.

We’ve included a chart snapshot here, and you can plainly see, the stock had been beaten back severely and is only just now beginning to mount a rebound.

Extended Watchlist:
DOLV, USRM, ICNB, ANW, CGG, ANTH